Main content

Molnupiravir and Drug Development at Emory

Emory University has discovered and advanced the development of some of the world’s most important and valuable antiviral drugs, successfully taking treatments from bench to bedside. 

As one of the nation’s leading research universities, a key mission for Emory is to improve lives and provide hope to everyone we serve in all facets of our work. The criteria by which we measure our success include but are not limited to the lives saved, partnerships forged, solutions provided to real-world issues, and the scientific discoveries and foundation developed that will improve the health, wellness and safety of individuals around the globe for generations to come.

About Molnupiravir 

Molnupiravir was invented at Emory University. Drug Innovation Ventures at Emory (DRIVE) LLC, which was formed by Emory to develop early-stage drug candidates for viral diseases of global concern, advanced molnupiravir through an Investigational New Drug submission. 

On Dec. 23, the U.S. Food and Drug Administration (FDA) announced that molnupiravir has received Emergency Use Authorization (EUA) for treatment of COVID-19.

The EUA authorizes the use of molnupiravir for “the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate.”


For more information, visit the Drug Discovery at Emory website.

Media Contact

Gana Ahn

Featured Stories

Recent News